DiaGenic ASA: Interim solution completed
25.07.2012 - Oslo-based DiaGenic ASA will have a new CEO in September: Paul de Potocki will succeed Henrik Lund, who has led the development of DiaGenic on an interim basis since April 2012.
Before de Potocki moved to DiaGenic, he was CEO of Aerocrine AB, a Swedish medical device and diagnostic company. Prior to joining Aerocrine, he served as Senior Vice President, Commercial and Strategic Development at Biovitrum AB. He has also served as Executive Vice President, Strategic Marketing at the German company Fresenius Kabi, as well as Divisional Vice President, Global Sales and Strategic Marketing with Pharmacia. Before this, he held various international commercial management positions within the Unilever group. Henrik Lund will resume his former position as chairman of DiaGenic.http://www.european-biotechnology-news.com/people/bio-people/2012-2/paul-de-potocki.html